Brokerages expect Kezar Life Sciences Inc (NASDAQ:KZR) to post earnings per share (EPS) of ($0.56) for the current quarter, Zacks reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.58) and the highest is ($0.53). Kezar Life Sciences reported earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%. The business is expected to report its next earnings results on Tuesday, March 24th.
On average, analysts expect that Kezar Life Sciences will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.87). For the next year, analysts anticipate that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.50). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.03.
A number of institutional investors and hedge funds have recently modified their holdings of KZR. Metropolitan Life Insurance Co NY bought a new position in Kezar Life Sciences in the first quarter worth $89,000. Acadian Asset Management LLC bought a new position in shares of Kezar Life Sciences during the second quarter valued at $107,000. A.R.T. Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the second quarter valued at $112,000. Wells Fargo & Company MN boosted its position in shares of Kezar Life Sciences by 302.5% during the second quarter. Wells Fargo & Company MN now owns 30,878 shares of the company’s stock valued at $238,000 after buying an additional 23,207 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Kezar Life Sciences by 24.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 35,057 shares of the company’s stock valued at $271,000 after buying an additional 6,854 shares during the last quarter. 49.24% of the stock is owned by institutional investors and hedge funds.
Shares of KZR stock traded up $0.26 during trading on Friday, hitting $3.38. The company had a trading volume of 797 shares, compared to its average volume of 156,105. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average is $3.23 and its two-hundred day moving average is $3.99. The stock has a market capitalization of $60.10 million, a price-to-earnings ratio of -1.46 and a beta of 1.08. Kezar Life Sciences has a 52 week low of $2.36 and a 52 week high of $24.16.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Featured Article: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.